Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Sagimet Biosciences Inc. Series A Common Stock

SGMT

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Last trade $9.73
Day change -$0.40 (-3.95%)
Day range $9.61 – $10.23
Volume 403,313
Market cap $729M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$728.71M
Price / earnings
—
Price / book
3.01×
Price / sales
—
EV / sales
—
EV / EBITDA
-10.32×

Profitability

Earnings per share
-$0.74
Return on assets
-18.9%
Return on equity
-22.02%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.34×
Quick ratio
6.34×
Cash ratio
2.92×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$43.66M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SGMT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$5.23M$4.28M$4.72M$4.03M$4.6M$4.68M$4.52M$3.98M
Research and development$16.34M$11.54M$7M$6.73M$9.73M$7.25M$15.34M$14.22M
Total operating expenses$21.57M$15.82M$11.71M$10.77M$14.33M$11.93M$19.87M$18.2M
Operating income-$21.57M-$15.82M-$11.71M-$10.77M-$14.33M-$11.93M-$19.87M-$18.2M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$19.15M-$13.95M-$10.65M-$9.57M-$12.91M-$10.39M-$18.18M-$16.2M
Income taxes$0$0$0$0$0$0$0$0
Net income-$19.15M-$13.95M-$10.65M-$9.57M-$12.91M-$10.39M-$18.18M-$16.2M
Net income attributable to common shareholders-$19.15M-$13.95M-$10.65M-$9.57M-$12.91M-$10.39M-$18.18M-$16.2M
EBITDA-$21.57M-$15.82M-$11.71M-$10.77M-$14.33M-$11.93M-$19.87M-$18.2M
Basic earnings per share-$0.31-$0.26-$0.33-$0.29-$0.40-$0.32-$0.56-$0.50
Diluted earnings per share-$0.31-$0.26-$0.33-$0.29-$0.40-$0.32-$0.56-$0.50

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet

Sagimet Biosciences (SGMT) has a mean analyst price target of $26.69, suggesting 168.2% upside potential from its current $9.95 price. The stock has a Zacks Rank #2 (Buy) rating with positive earnings estimate revisions, though the article cautions that analyst price targets can be misleading and should not be the sole basis for investment decisions.

GlobeNewswire Inc.

Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsight

The acne vulgaris market is expected to grow steadily through 2036, driven by increasing disease prevalence affecting 85% of adolescents and young adults, and a pipeline of emerging therapies. Key players including Ascletis Pharma, Sagimet Biosciences, AOB Pharma, and Kintor Pharmaceutical are developing novel treatments like Denifanstat (ASC40), TVB-3567, B244, and GT20029 to address unmet needs in moderate-to-severe and treatment-resistant acne. The U.S. holds the largest market share, with recent approvals including clascoterone (WINLEVI) and combination therapy CABTREO expanding treatment options.

GlobeNewswire Inc.

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

Sagimet Biosciences announced that its AURORA Phase 3 clinical trial of denifanstat, a FASN inhibitor for moderate to severe acne, is on track to begin patient enrollment in Q4 2026. All clinical trial sites have been identified and a CRO has been retained, with patient screening expected to start in October 2026. The trial will enroll approximately 800 U.S. patients, including 450 adolescents, and if approved, denifanstat would be the first innovative oral acne treatment in over 40 years.

GlobeNewswire Inc.

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

Sagimet Biosciences Inc. (Nasdaq: SGMT) announced its inclusion in the Russell 3000 and Russell 2000 indexes effective June 29, 2026. The clinical-stage biopharmaceutical company plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the second half of 2026. The company has sufficient capital to fund operations through 2028, including the denifanstat Phase 3 trial data readout.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.